Effect of monoamine oxidase inhibitors on qualitative alterations in enzymatic properties of mitochondrial monoamine oxidases.
D000818:Animals; D003300:Copper; D003641:Deamination; D006632:Histamine / Q000378:metabolism; D007490:Iproniazid / Q000494:pharmacology*; D008239:Lysine / Q000378:metabolism; D008297:Male; D008930:Mitochondria, Liver / Q000201:enzymology*; D008995:Monoamine Oxidase / Q000302:isolation & purification / Q000378:metabolism*; D009829:Oleic Acids; D010293:Pargyline / Q000494:pharmacology*; D011073:Polyamines / Q000378:metabolism; D011489:Protein Denaturation; D051381:Rats; D014191:Tranylcypromine / Q000494:pharmacology*; D014439:Tyramine / Q000378:metabolism
D009829:Oleic Acids; D011073:Polyamines; D014191:Tranylcypromine; D003300:Copper; D006632:Histamine; D010293:Pargyline; D007490:Iproniazid; D008995:Monoamine Oxidase; D008239:Lysine; D014439:Tyramine